Neuropharmacology & Neurotherapeutics
Natalizumab (trade name Tysabri) is an immunosuppressive drug used for the treatment of relapsing-remitting or relapsing secondary progressive multiple sclerosis, as a second-line therapy in patients who do not respond to first-line agents. It is a selective adhesion molecule inhibitor that blocks the ability of alpha4 beta1 integrin to bind to its receptor, the vascular cell adhesion molecule.
Mar. 01, 2021